

Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

1st October, 2021

Corporate Relationship Department M/s. BSE Ltd.
Dalal Sreet, Fort
Mumbai 400 001

Scrip Code: **524816**

Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) <u>Mumbai 400 051</u>

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for your information.

(NATCO)

Thanking you

Yours faithfully

For NATCO Pharma Limited

M. Adinarayana

Company Secretary &

Monarayana

Vice President (Legal and Corp Affairs)

Encl: as above



Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/ 15 /2021-22

Press Release

NATCO

NATCO Announces Launch of its 10mg strength for Everolimus Tablets (generic for Afinitor[®]) in the US market

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816: Announces today that its marketing partner Breckenridge Pharmaceutical, Inc., US has launched the 10mg strength of Everolimus Tablets (generic for Afinitor®) in the US market. The U.S. Food and Drug Administration previously granted final approval of this Abbreviated New Drug Application. According to industry sales data, the 10mg strength of Afinitor generated annual sales of \$392 million during the twelve months ending July 2021. Breckenridge previously launched Everolimus tablets in 2.5mg, 5mg and 7.5mg strengths during the first quarter of 2021 in the US market.

*All brand names and trademarks are the property of their respective owners.

Forwarded for favor of publication

For NATCO Pharma Limited

M Adinarayana

Company Secretary &

Vice President (Legal & Corp Affairs)